Streptokinase structure
|
Common Name | Streptokinase | ||
|---|---|---|---|---|
| CAS Number | 9002-01-1 | Molecular Weight | 197.274 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 343.9±35.0 °C at 760 mmHg | |
| Molecular Formula | C11H19NO2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 161.8±25.9 °C | |
Use of StreptokinaseStreptokinase is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion[1][2]. |
| Name | 4-cyclohexylpyrrolidine-2-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Streptokinase is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Sreptokinase (6000 IU/kg in 3 ml of saline; intracoronary; infused at 0.05 ml/min for 60 minutes beginning 30 minutes before reperfusion) maintains reperfusion coronary blood flow through a critical stenosis at a rate similar to baseline levels[2]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 343.9±35.0 °C at 760 mmHg |
| Molecular Formula | C11H19NO2 |
| Molecular Weight | 197.274 |
| Flash Point | 161.8±25.9 °C |
| Exact Mass | 197.141586 |
| PSA | 49.33000 |
| LogP | 1.99 |
| Appearance of Characters | lyophilized powder |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.517 |
| Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Hazard Codes | C,Xi |
|---|---|
| Risk Phrases | 36/37/38 |
| Safety Phrases | 22-24/25-36-26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | OB8880000 |


|
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Blood 84 , 680-6, (1994)
|
|
|
Primary coronary intervention versus thrombolytic therapy in myocardial infarction patients in the Middle East Al-Zakwani, I., et al.
J. Am. Med. Assoc. 34(3) , 445-51, (2012)
|
|
|
Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture Nikandrov, V., et al.
Biomed. Khim. 54 , 192-200, (2012)
|
| L-Proline,4-cyclohexyl-,(4S) |
| MFCD00082037 |
| Streptokinase |
| 4-Cyclohexylproline |
| 4-cyclohexyl-2-pyrrolidinecarboxylic acid |
| Proline, 4-cyclohexyl- |